Sangamo Therapeutics Reports Business Highlights and Second Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Sangamo Therapeutics (SGMO) Reports Q2 Loss of $0.26
August 5, 2020 4:43 PM EDTSangamo Therapeutics (NASDAQ: SGMO) reported Q2 EPS of ($0.26), versus ($0.26) reported last year. Revenue for the quarter came in at $21.55 million, versus $17.55 million reported last year.
For earnings history and earnings-related data on Sangamo Therapeutics (SGMO) click here.
... More